medigraphic.com

2007, Number 6

Next >>

Cir Cir 2007; 75 (6)

Impact of genomic signatures in the therapeutic decision of breast cancer

Rodríguez-Cuevas SA, Luna-Arias JP

Language: Spanish
References: 15
Page: 415-417
PDF size: 41.01 Kb.


Text Extraction

No abstract


REFERENCES

  1. 1. Early Breast Cancer Trialist’s Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomized trials. Lancet 2005;365:1687-1717.

  2. 2. André F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006;3:621-632.

  3. 3. D’Eredita G et al. Prognostic factors in breast cancer: the predictive value of the Nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-596.

  4. 4. Adjuvant On Line. Available at http://www.adjuvantonline.com/Accessed October 4, 2007.

  5. 5. Shak S, Baehner FL, Palmer G, et al. Subtypes of breast cancer defined by standardized quantitative RT-PCR analysis of 10,618 tumors. Breast Cancer Res Treat 2006;100(suppl 1):S295.

  6. 6. Paik S, Shak S, Tang G, et al. A multigene-assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.

  7. 7. Habel LA, Shak S, Jacobs M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25 (Available on line).

  8. 8. van de Vijver MJ, He YD, van’T Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.

  9. 9. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-1671.

  10. 10. Sparano JA, TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7:347-350.

  11. 11. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006;3:5040-5051.

  12. 12. Fan C, Oh DS, Wessels L, et al. Concordance among gene expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.

  13. 13. Hunter D, et al. New breast cancer susceptibility genes identified. Nature (May 27, 2007). Available on line http://www.medsacpe.com/viewarticle/557462.

  14. 14. Liu R, et al. Gene signature linked to breast cancer survival. N Engl J Med 2007:356:217-226, 294.

  15. 15. Hsu S, Herbst RS. Genomic signatures of drug sensitivity can predict response to treatment. J Clin Oncol 2007;25:4350-4357.




2020     |     www.medigraphic.com